Search Result

Results for "

PD-L1 ligand

" in MedChemExpress (MCE) Product Catalog:

By Targets:	E3 Ligase Ligand-Linker Conjugates (2) PD-1/PD-L1 (17) Target Protein Ligand-Linker Conjugates (2) Apoptosis (2) Autophagy (1) HIF/HIF Prolyl-Hydroxylase (1) LAG-3 (1) Ligands for Target Protein for PROTAC (2) PROTACs (1) STAT (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (22) Inflammation/Immunology (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Targets Recommended: PD-1/PD-L1 Target Protein Ligand-Linker Conjugates E3 Ligase Ligand-Linker Conjugates

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150879

BMS-37	PD-1/PD-L1 Ligands for Target Protein for PROTAC	Cancer
BMS-37 is a *PD-1/PD-L1* immune checkpoint inhibitor. BMS-37 can be used as PD-L1 ligand to synthesize PROTAC molecules .

HY-P3440

WL12	PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-P2474

Human PD-L1 inhibitor I	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 .

HY-N12687

Benzosceptrin C	PD-1/PD-L1 Apoptosis	Cancer
Benzosceptrin C is an inhibitor for *PD-L1, which promotes programmed cell death ligand* (PD-L1) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity .

HY-P99723

Manelimab

BCD-135
PD-1/PD-L1 Cancer

Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .

Manelimab BCD-135	PD-1/PD-L1	Cancer
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .

HY-158052

PD-1/PD-L1 antagonist 1	PD-1/PD-L1	Cancer
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC₅₀ of 23.78 nM .

HY-P9904

Atezolizumab 15+ Cited Publications MPDL3280A	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P99641

Gilvetmab

PD-1/PD-L1 Cancer

Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-128605

PD-1-IN-22

PD-1/PD-L1 Cancer

PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC₅₀ of 92.3 nM .

PD-1-IN-22	PD-1/PD-L1	Cancer
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC₅₀ of 92.3 nM .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to *PD-1, thereby blocking the interaction of PD-1* with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-145769

N2S2-CBMBC	PD-1/PD-L1	Cancer
N2S2-CBMBC, an N2S2 bromo-benzyl ether derivative, acts as a ligand and use ^99mTc-labelled complexes ^99mTc-N2S2-CBMBC can be used as an imaging agent to be applied to the aspect of detecting PD-L1 expression, realize the real-time, comprehensive and convenient detection of the PD-L1 level of tumors, and overcome the defects of an immunohistochemical method .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .

HY-N0596

Panaxadiol 20(R)-Panaxadiol	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT	Cancer
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .

HY-138139A

AXC-715 hydrochloride T785 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 . AXC-715, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

HY-138139B

AXC-715 trihydrochloride T785 trihydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 . AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor *PD-1* antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-131386A

BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride	Target Protein Ligand-Linker Conjugates	Cancer
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker. BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183). PROTAC PD-1/PD-L1 degrader-1 inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM .

HY-131386

BMS-1166-N-piperidine-CO-N-piperazine	Target Protein Ligand-Linker Conjugates	Cancer
BMS-1166-N-piperidine-CO-N-piperazine incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker. BMS-1166-N-piperidine-CO-N-piperazine can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183). PROTAC PD-1/PD-L1 degrader-1 inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM .

HY-131186

Pomalidomide-amido-C3-piperazine-N-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) .

HY-131187

BMS-1166-N-piperidine-COOH	Ligands for Target Protein for PROTAC	Cancer
BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1 . BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-130642

(S,R,S)-AHPC-Me-C10-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-C10-Br is a synthesized *E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901 .*

Cat. No.	Product Name

HY-L109

Protein-protein Interaction Inhibitor Library	576 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 576 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Protein-protein Interaction Inhibitor Library

576 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 576 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P3440

WL12	PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-P2474

Human PD-L1 inhibitor I	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 .

Cat. No.	Product Name	Target	Research Area

HY-P9904

Atezolizumab 15+ Cited Publications MPDL3280A	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P99723

Manelimab

BCD-135
PD-1/PD-L1 Cancer

Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .
HY-P99641

Gilvetmab

PD-1/PD-L1 Cancer

Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .

Manelimab BCD-135	PD-1/PD-L1	Cancer
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to *PD-1, thereby blocking the interaction of PD-1* with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor *PD-1* antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

Panaxadiol 20(R)-Panaxadiol	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Araliaceae Cancer	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .

Benzosceptrin C	Structural Classification Alkaloids Pyrrole Alkaloids Marine natural products Source classification	PD-1/PD-L1 Apoptosis
Benzosceptrin C is an inhibitor for *PD-L1, which promotes programmed cell death ligand* (PD-L1) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity .

Species:	Human (7) Rhesus Macaque (2) Rat (3) Mouse (4) Cynomolgus (2) Canine (1)
Tag:	His (8) Tag Free (1) Avi (1) Fc (10) Flag (1)
Source:	HEK293 (18) CHO (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73361

	PD-L1 Protein, Human (HEK293) 4 Publications Verification Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with tag free. The total length of PD-L1 Protein, Human (HEK293) is 220 a.a., with molecular weight of ~36 kDa.

HY-P73364

	PD-L1 Protein, Rat (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Rat (HEK293, Fc) is 221 a.a., with molecular weight of ~63 kDa.

HY-P73365

	PD-L1 Protein, Rat (HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of PD-L1 Protein, Rat (HEK293, His) is 221 a.a., with molecular weight of ~41.79 kDa.

HY-P73717

	PD-L1 Protein, Canine (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Canine	HEK293
	PD-L1 Protein, Canine (HEK293, Fc) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response. The amino acid sequence of PD-L1 is encoded by 7 exons, which form a protein of ~40 kDa. PD-L1 is a type I transmembrane protein, is part of the immunoglobulin (Ig) superfamily and is composed of IgV-like and IgC-like extracellular domains, a hydrophobic transmembrane domain and a short cytoplasmic tail composed of 30 amino acids. PD-L1 can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. PD-L1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Canine (HEK293, Fc) is 218 a.a., with molecular weight of ~70-80 & 140-160 kDa, respectively.

HY-P73716

	PD-L1 Protein, Mouse (HEK293, His-Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag. The total length of PD-L1 Protein, Mouse (HEK293, His-Fc) is 238 a.a., with molecular weight of 64-90 kDa.

HY-P77347

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is 239 a.a., with molecular weight of ~37.7 kDa.

HY-P73363

	PD-L1 Protein, Mouse (239a.a, HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (239a.a, HEK293, Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Mouse (239a.a, HEK293, Fc) is 239 a.a., with molecular weight of ~51.6 kDa.

HY-P77348

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is 239 a.a., with molecular weight of ~26.7 KDa.

HY-P70657

	PD-L1 Protein, Human (HEK293, mFc) Programmed Cell Death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed Death ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of PD-L1 Protein, Human (HEK293, mFc) is 221 a.a., with molecular weight of 59-89 kDa.

HY-P70663

	PD-L1 Protein, Human (HEK293, Flag) Programmed Cell Death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed Death ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, Flag) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Flag labeled tag. The total length of PD-L1 Protein, Human (HEK293, Flag) is 221 a.a., with molecular weight of 35-40 kDa.

HY-P70672

	PD-L1 Protein, Human (221a.a, HEK293, Fc) Programmed Cell Death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed Death ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (221a.a, HEK293, Fc) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Human (221a.a, HEK293, Fc) is 221 a.a., with molecular weight of 70-80 kDa.

HY-P70721

	PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) Programmed Cell Death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. The total length of PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is 221 a.a., with molecular weight of 70-95 kDa.

HY-P70564

	PD-L1 Protein, Cynomolgus (HEK293, His) B7-H; B7H1; B7-H1; PDCD1L1; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, His) is 221 a.a., with molecular weight of 32-40 kDa.

HY-P70632

	PD-L1 Protein, Mouse (HEK293, His) Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Mouse (HEK293, His) is 220 a.a., with molecular weight of 38-58 kDa.

HY-P70633

	PD-L1 Protein, Mouse (220a.a, HEK293, Fc) Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274;	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (220a.a, HEK293, Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Mouse (220a.a, HEK293, Fc) is 220 a.a., with molecular weight of 66-90 kDa.

HY-P7397

	PD-L1 Protein, Human (CHO, Fc) rHuPD-L1, Fc Chimera; Programmed death ligand 1; CD274; B7-H1	Human	CHO
	PD-L1 Protein, Human (CHO, Fc) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P7398

	PD-L1 Protein, Human (HEK293, His) rHuPD-L1, His; Programmed death ligand 1; CD274; B7-H1	Human	HEK293
	PD-L1 Protein, Human (HEK293, His) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P71008

	PD-L1 Protein, Cynomolgus (HEK293, Fc) B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, Fc) is 221 a.a., with molecular weight of ~73.0 kDa.

HY-P70814

	PD-L1 Protein, Rat (221a.a, HEK293, His) B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Rat	HEK293
	PD-L1 Protein is a type I transmembrane protein that belongs to the immunoglobulin (Ig) superfamily. PD-L1 can interact with PD-1, and PD-1/PD-L1 axis is responsible for T cell activation, proliferation, and cytotoxic secretion in cancer, and regulates anti-tumor immune responses. PD-L1 plays a major role in suppressing the adaptive arm of immune systems. PD-L1 Protein, Rat (221a.a, HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Rat (221a.a, HEK293, His) is 221 a.a., with molecular weight of 40-60 kDa.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks